ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.
Orchid Pharma's Q1FY27 revenue grew 15% YoY to INR 304Cr, with EBITDA rising to INR 25Cr. The company is pivoting toward complex, high-value molecules and backward integration.
Management reports a recovery in Q1 FY27 with 15% revenue growth after a difficult FY26, but remains cautious due to industry-wide overcapacity and pricing pressure.
Orchid Pharma reported strong Q1FY27 performance following the strategic amalgamation of Dhanuka Laboratories, transforming into an integrated cephalosporin platform with a significant turnaround in profitability metrics.
Orchid Pharma filed its Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations regarding its prior QIP issue.
Orchid Pharma Ltd reported revenue from operations of ₹368.3 Cr (+3.0% YoY) and net profit of ₹25.8 Cr (-24.1% YoY) for Q4 FY26.
Orchid Pharma Ltd reported revenue from operations of ₹304.2 Cr (+15.6% YoY) and net profit of ₹3.2 Cr for Q1 FY27.
Orchid Pharma Limited has scheduled a board meeting for August 14, 2026, to consider and approve its Q1 FY 2026-27 financial results and restated annual results.
Orchid Pharma allotted 4,45,86,052 equity shares to shareholders of Dhanuka Laboratories Limited, following the approved scheme of amalgamation.
Orchid Pharma has scheduled a board meeting for August 1, 2026, to approve share allotments related to the amalgamation with Dhanuka Laboratories Limited.
Orchid Pharma Ltd has filed its quarterly shareholding pattern as of June 30, 2026, disclosing the promoter and public shareholding distribution.
Orchid Pharma announced that the merger of Dhanuka Laboratories Limited is now effective. Dhanuka Laboratories stands dissolved following the filing of NCLT orders with the ROC.
Orchid Pharma signed a licensing deal with Russia's Pharmasyntez, unlocking a $178M opportunity. This 10-year pact for Exblifep® marks a major international expansion for the Indian pharma firm.
Orchid Pharma received a Rs.1.67 Crore GST demand for an erroneously refunded amount. The company believes the order is unjustified and plans to appeal.
NCLT Chennai has sanctioned the merger of Dhanuka Laboratories Limited with Orchid Pharma Limited. This approval facilitates the legal consolidation of operations and assets on a going-concern basis.
Orchid Pharma reports FY26 standalone revenue of ₹811cr and EBITDA of ₹101cr. Strategy shifts towards platform creation, including the Dhanuka merger and entering the U.S. sterile formulation market.
Orchid Pharma Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report details statutory compliance status and historical observations.
Orchid Pharma is pivoting from a recovery phase to a higher-margin 'platform creation' model, integrating Dhanuka Laboratories and aggressively targeting the US sterile cephalosporin market.
Orchid Pharma reports FY26 standalone revenue of ₹811 Cr and PAT of ₹45 Cr, focusing on transitioning from a turnaround to an integrated cephalosporin platform with major capex in 7ACA.
Orchid Pharma appointed M/s. T R Chadha & Co. LLP as its Internal Auditor for a 12-month term. The appointment strengthens the company's internal control and governance frameworks.
Orchid Pharma Ltd reported revenue from operations of ₹237.6 Cr (+0.0% YoY) and net profit of ₹23.8 Cr (+6.7% YoY) for Q4 FY26.
Orchid Pharma approved audited FY2026 results and appointed T R Chadha & Co. LLP as internal auditors. The consolidated net profit for the year stood at ₹21.21 Crore.
Orchid Pharma scheduled a board meeting for May 25, 2026, to approve fiscal 2026 audited financial results. The trading window remains closed until 48 hours post-declaration.
Orchid Pharma Limited submitted its Monitoring Agency Report for the Rs. 400 Crore QIP. The funds are being utilized as per revised shareholder-approved objects.
The National Company Law Tribunal (NCLT), Chennai Bench, dismissed an application filed by DBS Bank against Orchid Pharma Limited. The claim involved lease rent dues during the Corporate Insolvency Resolution Process (CIRP) period. The tribunal's order, dated April 02, 2026, has no quantifiable financial impact on the company.